CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue:
Genetic testing	$ 347,900	$ 420,333
Other	55,312	67,233
Total revenue	403,212	487,566
Cost of revenue	331,041	394,771
Gross profit	72,171	92,795
Operating expenses:
Research and development	182,530	209,176
Selling, general and administrative	1,562,791	1,526,606
Amortization of intangibles	19,414	23,525
Total operating expenses	1,764,735	1,759,307
Loss from operations	(1,692,564)	(1,666,512)
Other income (expense):
Interest income	222	1,993
Interest expense	(150,853)	0
Total other income (expense)	(150,631)	1,993
Loss before income taxes	(1,843,195)	(1,664,519)
Benefit for income taxes	0	0
Net loss	$ (1,843,195)	$ (1,664,519)
Basic and diluted net loss per common share (in dollars per share)	$ (0.01)	$ (0.01)
Weighted average common shares outstanding, basic and diluted (in shares)	172,737,553	122,481,674